Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Internal Medicine
Anifrolumab
Questions discussed in this category
Would you consider anifrolumab in the management of hematologic manifestations in SLE?
2 Answers available
13193
Papers discussed in this category
N Engl J Med, 2019 Dec 18
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Ann Rheum Dis, 2022 Mar 25
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Lupus science & medicine, 2018
Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE.
Arthritis Rheum,
Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Related Topics in Internal Medicine
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers